Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment.

Introduction

In 1980, an international group of pathologists and clinicians led by Basil Morson published a critical review entitled Precancerous Conditions and Epithelial Dysplasia in the Stomach.1 This seminal article attempted to merge Eastern and Western pathological experiences in the evaluation of preneoplastic conditions into a systematic approach to the evaluation of gastric precancerous conditions. Thirty-five years after its publication, we pay homage to Professor Morson's team by revisiting their positions in light of the dramatic advances of our understanding of gastric disease that have occurred during this time. To this end, we have selected from the original article those statements that warranted reappraisal and, after reproducing them verbatim, have provided our comments.

Introduction

When considering problems of pre-malignancy, it is essential to define exactly what is meant by this term. A distinction can be made between a precancerous condition and a precancerous lesion. The former is best regarded as a clinical state associated with a significantly increased risk of cancer, whereas a precancerous lesion is a histopathological abnormality in which cancer is more likely to occur than in its apparently normal counterpart. In many clinical conditions with an increased risk of cancer, there is also an identifiable precancerous lesion, but this is not invariably so.

Studies carried out in the last three decades have supported the multifactorial aetiology of sporadic gastric cancer and have led to the concept of a progressive ‘cascade’ of phenotypic and molecular changes that may eventually result in neoplasia.2 In 1994, Helicobacter pylori was added to the cascade, providing the hitherto missing crucial aetiological element that initiates the entire process.3 4 While the distinction between precancerous condition and lesion remains useful, the current understanding of gastric oncogenesis (including its early molecular disarrangements) begs an expansion of the concept of ‘lesion’, which should not only refer to focal changes (eg, dysplasia) as envisioned by Morson, but should also cover the spectrum of the organic (histological and molecular) abnormalities associated with an increased gastric cancer risk. In keeping with the concept that both H. pylori gastritis and autoimmune gastritis confer a small, but measurable increased risk for gastric cancer, we suggest that they be considered part of the spectrum of early precancerous lesions (the former Morson's conditions).5 Intraepithelial neoplasia (Morson's dysplasia) can be viewed as the most advanced stage of the premalignant cascade (table 1; figure 1).

Table 1

Gastric precancerous Conditions and Lesions

Precancerous conditions	Precancerous lesions
H. pylori-associated gastritisAutoimmune gastritisGastric (chronic) ulcerGastric stumpsSyndromic neoplastic diseases: Li-Fraumeni syndrome Hereditary breast and ovarian cancer Lynch Syndrome MUTYH-associated adenomatous polyposis (MAP) Juvenile polyposis syndrome PTEN hamartoma tumour syndrome (PHTS)	Early precancerous lesions (H. pylori-associated gastritis, Autoimmune gastritis)
	▸ Gastritis Stage O
	▸ Gastritis Stage I
	▸ Gastritis Stage II
	▸ Gastritis Stage III
	▸ Gastritis Stage IV
	Advanced precancerous lesions (H. pylori, Autoimmune, Syndromic neoplasia)
	▸ Intra-Epithelial Neoplasia Low-grade (IEN-LG)
	▸ Intra-Epithelial Neoplasia High-grade (IEN-HG)

Precancerous Conditions: clinically-defined diseases associated to increased (gastric and non-gastric) cancer risk, in which precancerous lesions may occur.

Precancerous Lesions: organic modification of the native mucosal status (at both phenotypic and molecular levels).

Gastritis stages recapitulate the multistep inflammatory/atrophic involvement of the gastric mucosa (mainly due to Helicobacter infection): their precancerous meaning is expected to increase along with the severity of the mucosa atrophy, as expressed by the gastritis stage.

Advanced precancerous lesions are basically focal, and mainly restricted to patients harboring extensive atrophic lesions (high-risk stages; Stages III and IV).

MUTYH–gene (located on chromosome 1p35); PTEN-gene (located on chromosome 10q22–23).

Figure 1

Model of Helicobacter pylori-associated lesions according to gastric oncogenetic cascade. The organic lesions are also expressed in terms of gastritis stage. Grey, normal mucosa; Green, H. pylori; Light red, mucosa inflammation; Yellow, mucosa atrophy (with or without intestinal metaplasia (IM)); Violet, advanced precancerous lesion (intraepithelial neoplasia) at the angularis incisura.

Lesions arising from mucosal-associated lymphoid tissue (MALT) should now be viewed as part of a continuum that may progress to a lymphoid malignancy. At the time of Morson's writing, MALT lymphomas (more recently renamed as marginal zone B cell lymphomas) were categorised as pseudo-lymphomas, a heterogeneous spectrum of histological abnormalities, including lymphoid hyperplasia, lymphoid proliferation ‘at the interface between benign and malignant’ and low-grade lymphoid neoplasia. Current evidence is unequivocal about the preneoplastic nature of these lesions.6–8

With the exception of autoimmune atrophic gastritis, whose aetiology remains uncertain (see below), the common denominator in the prevention of all precancerous lesions as defined above is the eradication of H. pylori.

Atrophic gastritis

This is a histological diagnosis. The main features are a variable degree of inflammation, atrophy of gastric glands, and often associated intestinal metaplasia, with changes more commonly found in the antrum than in the body or the fundus of the stomach.….

Most intestinal-type gastric cancers develop in atrophic mucosa; thus, the assessment of gastric mucosal atrophy is a crucial step in the identification of at-risk patients.9 10 Although we are in agreement with Morson's statement that atrophic gastritis ‘is a histological diagnosis’, the last 35 years have witnessed the development of new technologies that, while not replacing histology, provide useful adjuncts to the detection of gastric atrophy. The most notable are new endoscopic instruments that provide a view of the gastric mucosa unimaginable 35 years ago. Magnification endoscopy, autofluorescence, narrow-band imaging and blue-laser imaging allow endoscopists to gather reliable information on the distribution and extension of atrophy, thus helping to better select areas for biopsy sampling.11–13

The loss of gastric glands can be functionally tested by measuring their circulating products. Serum pepsinogen I (PgI) and pepsinogen II (PgII) are the most reliable markers of functional mucosal atrophy: PgI, synthesised and secreted by chief cells, reflects the functional status of the oxyntic mucosa; PgII is produced by both oxyntic and antral mucosa. Multiple studies have shown a lower PgI/PgII ratio in patients with corpus atrophy, irrespective of its aetiology.14 15 When integrated with the serological evaluation of antibodies against Helicobacter, parietal cells and intrinsic factor, the Pg values and their ratio can provide a non-invasive and affordable estimate of gastric function and morphology. Some authors have referred to this battery of tests as the ‘serological biopsy’. While the serological biopsy now fills a useful niche in epidemiological studies, both endoscopic and histological assessments of atrophy continue to play the central role in clinical practice. Since the staging of atrophy and the determination of its aetiology are necessary steps in the evaluation of cancer risk, biopsy sets representative of both antrum and corpus are indispensable. The sampling protocols proposed by the Updated Sydney System and subsequently endorsed by both the Operative Link for Gastritis Assessment (OLGA) and the Operative Link on Gastric Intestinal Metaplasia (OLGIM) staging systems are adequate and are most useful when accompanied by sampling of any visible lesions.16–19

Patients with atrophic gastritis are statistically at increased risk from cancer of the stomach, but precise measurement of this risk is yet to be determined.

The OLGA Staging System is an instrument built on the natural history of gastric atrophy and its associated cancer risk. Proposed in 2005 by an international group of gastroenterologists and pathologists,17–19 it borrows its staging framework from the oncology vocabulary20 and ranks the histological phenotypes of gastritis along a scale (0–IV) of increasing mucosal atrophy. The cancer risk associated with stages 0, I and II, while not absent,5 is extremely low, while stages III and IV (characterised by extensive atrophy of both antral and oxyntic mucosa) are associated with high risk of intestinal-type gastric cancer. An alternative staging method proposed as a modification of the OLGA System (OLGIM) bases its stage assessment exclusively on the extension of IM, as assessed in both antral and oxyntic biopsy samples.19 While both systems have strengths and weaknesses, they have proved useful in the prognostication of cancer risk by allowing the placement of patients at approximate points along the path where chronic gastritis advances from the reversible inflammatory lesions (generally most severe in the antrum) to the extensive atrophic changes involving both antrum and corpus.21 22 While we still lack large-scale prospective population studies, the available information consistently associates a negligible risk of cancer with the 0–I–II stages. Because high-risk stages (III–IV) correlate with low serum levels of Pgs (particularly PgI), and low PgI/PgII ratios, Pg serology has been proposed as a non-invasive method for the initial assessment of atrophy in clinical practice.18 23 The clinical reliability of the morphological versus functional correlation still deserves to be further addressed.

Within the histological spectrum of atrophic gastritis intestinal metaplasia is the most sensitive risk indicator…

This statement, which represents the rationale for the OLGIM System, remains fundamentally valid: the extent of metaplastic transformation, particularly when combined with histochemical subtyping, parallels the cancer risk.24 25 The metaplastic transformation of the native gastric glands results into a loss of appropriate glands; hence, the inclusion of metaplasia in the definition of gastric mucosa atrophy.26 Native gastric glands can be replaced by two types of structures: (i) intestinal-type glands (enterocytes, goblet and Paneth cells; ie, IM) and (ii) pyloric-type glands (‘pseudo-pyloric metaplasia’). IM has traditionally been classified into small intestinal type, with well-spaced goblet cells and a brush border lining the enterocytes, and colonic type, with a more disorderly architecture and no brush border.27

By staining mucins with high iron diamine, IM has been further subtyped as Type I (complete or small intestinal type) and Types II and III (incomplete or colonic type). Several studies have associated colonic type IM (mostly III) with the highest risk for neoplastic transformation. However, because the proportion of Type III metaplasia is exponentially related to the extent of mucosal intestinalisation,25 the histology score of IM (as assessed by appropriate endoscopic biopsy mapping) can be considered as related to the cancer risk. Recently, it has been demonstrated that the high-risk gastritis stages (OLGA stages III and IV) feature mostly Type II and III IM, which incorporates the prognostic message obtainable from histochemical gastric mucin subtyping within the staging messages.21

Pseudo-pyloric metaplasia, now referred to as spasmolytic polypeptide-expressing metaplasia (SPEM), is the metaplastic replacement of oxyntic glands by mucin-secreting antral-like glands.28 29 The identification of SPEM, which occurs only in the oxyntic mucosa, is contingent upon the accurate topographic identification of the sample. SPEM, found in virtually all forms of atrophic gastritis, also represents the earliest phase of the atrophic transformation in autoimmune gastritis. In H. pylori infection, the cephalad spreading of the mucosal damage is associated with an enlarging ‘lawn’ of metaplastic pyloric-type epithelium, which commonly coexists with the intestinalisation of the distal gastric mucosa. Studies in animal models have confirmed SPEM as the first expression of atrophy and have helped elaborate hypotheses regarding its role in the development of IM.28

Pernicious anaemia

There is statistical and histological evidence that patients with pernicious anaemia are at increased risk from cancer of the stomach. True adenomatous polyps and carcinoma of the stomach have been reported to be three to four times more common in patients with pernicious anaemia than in the general population, although a recent study suggests that this may be an underestimate, since some patients with carcinoma but without overt pernicious anaemia are in a “pre-pernicious anaemia stage.

Pernicious anaemia is the result of long-standing cobalamin deficiency caused by advanced oxyntic mucosal atrophy.30 31 In its original description, this corpus-restricted atrophic gastritis was assumed to be primarily due to an autoimmune attack directed at parietal cells. In the last decades, however, atrophy has been most consistenly associated with long standing H.pylori infection. In addition, it has been suggested that H. pylori infection might also trigger and sustain an immune-mediated attack against the proton pump, resulting in organic lesions (ie, corpus-restricted atrophic gastritis) identical to those of primary gastric autoimmunity.32

This widened pathogenetic spectrum of oxyntic atrophy should also include the overlap of primary and secondary (post-infectious) autoimmune conditions. Because it is difficult to reliably discriminate between primary and secondary autoimmune corpus atrophy in epidemiological studies, both impact and magnitude of the cancer risk associated with each of its variants remain unknown.33 A study based on the OLGA staging suggests that the risk for precancerous lesions and cancer is only increased when autoimmune gastritis coexists, or has coexisted, with H. pylori infection.34 However, researchers from the US National Cancer Institute have recently provided evidence that subjects with pernicious anaemia are at increased risk for non-cardia gastric cancers and carcinoids.35 While this elegant study supports recent recommendations to consider surveillance in subjects with advanced atrophy and metaplasia, irrespective of pernicious anaemia,36 it does not address the question of whether the gastric cancer risk in patients with atrophic gastritis is related to previous exposure to Helicobacter.

Recent data suggest that SPEM associated with the early phase of corpus-restricted autoimmune gastritis may progress to more advanced precancerous lesions, but the SPEM-associated cancer risk remains unknown.37

Gastric polyps

Polypoid lesions of the stomach can be divided into those with and without malignant potential. The common ones, hyperplastic or regenerative polyps, have insignificant malignant potential. Polypoid lesions in which the epithelium shows dysplasia (which are called adenomas or borderline lesions by some) have a significant capacity for malignant change.

The proportions of the different types of gastric polyps encountered at esophago-gastric-duodenoscopy (EGD) have changed substantially in the last three decades.38 39 The industrialised world has experienced a progressive decrease of H. pylori infection and its related conditions, the use of proton pump inhibitors (PPI) has become widespread and indications for esophago-gastric-duodenoscopy have placed a greater emphasis on GORD, Barrett's oesophagus and the early detection of oesophageal adenocarcinoma. Thus, while Morson's major concerns lay in the detection of adenomas (dysplastic lesions with malignant potential) and hyperplastic polyps (even then recognised as having ‘insignificant malignant potential’), today more than 80% of the polyps detected in Western countries consist of fundic gland polyps in the vast majority of cases associated with chronic proton pump inhibitor use. In countries with high H. pylori prevalence, most polyps are of the hyperplastic-inflammatory type.38 39

Whereas non-neoplastic epithelial polyps have only a minimal influence on gastric cancer risk, sporadic neoplastic (adenomatous) polyps have a biological and clinical behaviour similar to that of neoplastic intraglandular lesions arising in flat (non-rising, non-polypoid) mucosa. The larger an adenomatous polyp, the greater its risk of containing foci of adenocarcinoma. Synchronous adenocarcinomas in other areas of the stomach have been reported in up to 30% (23/77) of patients with adenomas containing foci of invasive cancer.40 Thus, although the relative prevalence of the different types of polyps has changed, Morson's views regarding the cancer risk of gastric (adenomatous) polyps remain valid today.

Epithelial dysplasia

Attention has so far been concentrated on the above precancerous conditions and much less emphasis has been placed on epithelial dysplasia in the stomach as a marker for increased cancer risk. It is important that dysplasia should be defined and its significance evaluated as a possible marker common to all the above precancerous conditions. The main histological and cytological features of epithelial dysplasia are cellular atypia, abnormal differentiation, and disorganised mucosal architecture. These can occur in ordinary gastric (foveolar) epithelium as well as in intestinal metaplasia, both of which may be the source of carcinoma.

Morson and colleagues described gastric dysplasia as a precancerous lesion resulting from the concurrence of three main cytological and histological changes: (i) epithelial atypia; (ii) loss of epithelial commitment and (iii) disrupted mucosal architecture. In the Japanese literature, similar lesions had been labelled as borderline lesions, atypical epithelium or group 3 lesions.41

Since the early 1990s, a growing body of molecular studies have detected genotypic changes in dysplastic epithelia that are also found in invasive carcinomas. Based on both their cancer-like morphological abnormalities and their mutated molecular profiles, dysplastic epithelia were reclassified as neoplastic. This resulted in the creation of two major categories within the spectrum of neoplastic disease: (i) non-invasive neoplasia (formerly, dysplasia) and (ii) the invasive/infiltrative neoplasia. In the gastric oncogenic cascade, non-invasive neoplasia (synonyms: intraepithelial, intraglandular) represents the biological bridge between early precancerous lesions (atrophy and metaplasia) and early gastric cancer.42 43 Subsequently, intraepithelial neoplastic lesions were further segmented in two clinicobiological grades (low-grade and high-grade), the latter with a greater risk of progression to invasive cancer.

Different classifications of neoplastic intraepithelial lesions have been proposed. Both the Padova International44 and the WHO classification45 specifically addressed the precancerous lesions arising in gastric mucosa. The Vienna classification has proven to be problematic in its attempt to provide a pan-GI tract system to classify all precancerous diseases occurring in the anatomically diverse structures between the oral cavity and the anal mucosa.46

Clinical implications and further research

It is important to realise that the degree of risk associated with epithelial dysplasia is not yet established. Severe dysplasia on its own is not an indication for surgical intervention. However, experience of epithelial dysplasia in other organs suggests the importance of close follow-up for individual patients (including endoscopy and biopsy).

Significant progress has been made in our understanding of the course of advanced precancerous lesions owing to the invaluable contribution of a number of long-term follow-up studies. Solid evidence supports the promoting role of H. pylori, even in the advanced stages of the precancerous cascade. Accordingly, eradication is recommended even in the presence of advanced lesions.47 Low-grade intraepithelial lesions are known to be associated with a risk of cancer progression that increases in the presence of both H. pylori infection and extensive atrophy or metaplasia (high-stage gastritis). This evidence provides the rationale for endoscopic follow-up. The cancer risk associated with a validated diagnosis of a high-grade lesion (ie, confirmed by another experienced histopathologist) is extremely high and represents an indication for resection, now made much less invasive by the availability of endoscopic mucosal and submucosal resection.

More than 15 years ago, linkage analysis implicated germline mutations in the CDH1 tumour-suppressor gene (encoding the protein E-cadherin) as primary involved in the onset of hereditary signet-ring gastric carcinoma. The extremely high prevalence of both stomach and breast cancers in these patients currently suggests gastrectomy as the only secondary prevention strategy: molecular disarrangements, however, are probably more extensively involved in gastric cancer pathogenesis, even in its sporadic variants. How both host and environmental components may interact in modulating cancer risk will likely dominate the gastric cancer research landscape for the next 35 years.48

Conclusions

The biological, diagnostic and therapeutic panorama has dramatically changed in the 35 years since the publication of Morson's seminal paper. The discovery of H. pylori has revolutionised practice of gastroenterology and the script of Correa's oncogenic cascade has found its lead actor (figure 1). Lesions and conditions viewed as idiopathic in Morson's times are now known to be caused by H. pylori infection and have become curable. The recent interest in large, even nationwide H. pylori eradication programmes as a mean to eliminate gastric cancer will require implementation of this strategy at the population level and will have to be fully integrated into national healthcare priorities. The revised distinction between early and advanced precancerous lesions and the recognition that the extension of metaplastic atrophy is a reliable marker for gastric cancer risk have made possible more targeted and cost-effective surveillance strategies. These should be implemented using efficient delivery systems with a timely referral for positive test. Such measures, coupled with the wide availability of standardised treatment regimens based on clinical efficacy, side effects, simplicity, duration and cost, could make the near eradication of gastric cancer an achievable goal in many parts of the world.49 50